Evidence map›Paper›PMID 42387328›Full record

ArticleThe Journal of international medical research2026

Effects of adrenal ablation on blood pressure and target organ damage in deoxycorticosterone acetate-salt hypertensive rats.

Jindong Wan, Tao Luo, Ruixue Duan, Xinquan Wang, Qianwei Yang, Jixin Hou, Yidan Wang, Yuhang Lv, Qianyue Ran, Sen Liu and 1 more

Abstract read
In one paragraph

Article in The Journal of international medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jindong WanDepartment of Cardiology, School of Clinical Medicine, The First Affiliated Hospital of Chengdu Medical College, China.ORCID 0009-0003-2954-4765
Tao LuoDepartment of Cardiology, School of Clinical Medicine, The First Affiliated Hospital of Chengdu Medical College, China.
Ruixue DuanDepartment of Cardiology, School of Clinical Medicine, The First Affiliated Hospital of Chengdu Medical College, China.
Xinquan WangDepartment of Cardiology, School of Clinical Medicine, The First Affiliated Hospital of Chengdu Medical College, China.
Qianwei YangDepartment of Cardiology, School of Clinical Medicine, The First Affiliated Hospital of Chengdu Medical College, China.
Jixin HouDepartment of Cardiology, School of Clinical Medicine, The First Affiliated Hospital of Chengdu Medical College, China.
Yidan WangDepartment of Cardiology, School of Clinical Medicine, The First Affiliated Hospital of Chengdu Medical College, China.
Yuhang LvDepartment of Cardiology, School of Clinical Medicine, The First Affiliated Hospital of Chengdu Medical College, China.
Qianyue RanDepartment of Cardiology, School of Clinical Medicine, The First Affiliated Hospital of Chengdu Medical College, China.
Sen LiuDepartment of Cardiology, School of Clinical Medicine, The First Affiliated Hospital of Chengdu Medical College, China.
Peijian WangDepartment of Cardiology, School of Clinical Medicine, The First Affiliated Hospital of Chengdu Medical College, China.ORCID 0000-0002-3622-4538

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundPrimary aldosteronism is a common and underdiagnosed form of secondary hypertension. However, preclinical investigations of adrenal ablation as a potential therapeutic approach for primary aldosteronism treatment are limited.MethodsA deoxycorticosterone acetate-salt hypertensive rat model was established, and the animals were treated with either unilateral adrenal ablation or oral spironolactone for 12 weeks. Blood pressure was continuously monitored throughout the study period. The key endpoints included blood pressure regulation, circulating hormone levels, and target organ damage.ResultsAdrenal ablation markedly reduced blood pressure in deoxycorticosterone acetate-salt hypertensive rats. During the first 8 weeks of treatment, the antihypertensive effect exerted by adrenal ablation was significantly greater than that achieved using oral spironolactone. After 8 weeks, the blood pressure-lowering effects of both interventions were comparable, although each effect remained significantly lower than that in the untreated controls. Moreover, adrenal ablation was more effective than spironolactone in attenuating the target organ damage associated with deoxycorticosterone acetate-salt hypertension.ConclusionsCompared with oral spironolactone, adrenal ablation significantly lowered blood pressure and more effectively attenuated target organ damage in deoxycorticosterone acetate-salt hypertensive rats.

Indexed as

AdrenalectomyAdrenal GlandsBlood PressureHyperaldosteronismHypertensionAldosteroneAnimalsDesoxycorticosterone AcetateDisease Models, AnimalKidneyMaleRatsSpironolactoneAldosteroneDesoxycorticosterone AcetateSpironolactoneadrenal ablationblood pressure reductionDeoxycorticosterone acetate–salt hypertensive ratspironolactonetarget organ remodeling

Identifiers

PMID42387328
PMCPMC13329105

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.